がん診断の日本市場2019-2023

調査会社Venture Planning Group社が発行したリサーチレポート(データ管理コード:VPG906176)
◆英語タイトル:Japan Cancer Diagnostics Market Analysis, 2019-2023: Supplier Shares and Strategies, Emerging Tumor Markers, Volume and Sales Segment Forecasts, Technology and Instrumentation
◆発行会社/調査会社:Venture Planning Group
◆商品コード:VPG906176
◆発行日:2019年5月
◆調査対象地域:日本
◆産業分野:医療
◆ページ数:590
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Local PDFUSD7,600 ⇒換算¥836,000見積依頼/購入/質問フォーム
Global PDFUSD9,500 ⇒換算¥1,045,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Venture Planning Group社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[がん診断の日本市場2019-2023]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

VPGMarketResearch’s new report is a study of the major business opportunities emerging in the Japanese cancer diagnostics market during the next five years. The report examines trends in the Japanese cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Japan Market Overview

- Five-year test volume and sales projections.

- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.

- Estimated universe of laboratories performing cancer diagnostic testing.

- Cancer statistics, etiology and recent developments.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.

- ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

- Sales and market shares of major cancer diagnostic product suppliers by individual test.
- Five-year test volume and sales forecasts for major tumor markers by market segment, including:

- Hospitals
- Commercial/Private Laboratories

Instrumentation Review

- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

- Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

- Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

- The companies analyzed in the report include:

- Abbott
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Clinical Genomics
- Decode Genetics
- DiaSorin
- Diazyme
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic
- Janssen Diagnostics
- Leica Biosystems
- Kyowa Medex
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- PerkinElmer
- Polymedco
- Qiagen
- Quest Diagnostics
- Roche
- Scienion
- Sequenom
- Siemens Healthineers
- Takara Bio
- Theradiag
- Thermo Fisher
- Tosoh
- Vermillion
- Wako Pure Chemicals

Contains 590 pages and 95 tables

*** レポート目次(コンテンツ)***

http://www.LeadingMarketResearch.com/pdffiles/LOTJapanCancerDiagnosticsMarketTowardaNewFutureforTumorMarkersR&D.pdf

http://www.vpgcorp.com/webfiles/CANCER/CancerCompanyProfiled.pdf

*** 掲載企業 ***

Competitive Assessments

- Abbott
- Affymetrix
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- Cepheid
- Diamedix
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujirebio
- Grifols
- GSK Biologicals
- Hologic
- Leica Biosystems
- Lonza
- Ortho-Clinical Diagnostics
- PerkinElmer
- Qiagen
- Roche
- Scienion
- Sequenom
- SeraCare
- Siemens Healthineers
- Takara Bio
- Thermo Fisher
- Wako

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(VPG906176 )"がん診断の日本市場2019-2023" (英文:Japan Cancer Diagnostics Market Analysis, 2019-2023: Supplier Shares and Strategies, Emerging Tumor Markers, Volume and Sales Segment Forecasts, Technology and Instrumentation )はVenture Planning Group社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。